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ABSTRACT
Introduction and Aims: Osteolytic bone metastases are observed in advanced cases 
of breast cancer. In vitro data suggest that the activity of the calcium-sensing receptor 
(CaSR) expressed by metastatic cells could potentiate their osteolytic potential. This 
study aimed to demonstrate in vivo the involvement of the CaSR in breast cancer cells 
osteolytic potential and to identify potential targets linked to CaSR activity.
Methods and Results: MDA-MB-231 stably transfected with plasmids containing 
either a full-length wild-type CaSR (CaSR-WT), or a functionally inactive dominant 
negative mutant (CaSR-DN) or an empty vector (EV) were intratibially injected 
into Balb/c-Nude mice. X-ray analysis performed 19 days after injection showed a 
dramatic increase of osteolytic lesions in mice injected with CaSR-WT-transfected 
cells as compared to mice injected with EV- or CaSR-DN-transfected cells. This was 
associated with decreased BV/TV ratio and increased tumor burden. Epiregulin, an 
(*)OLNHOLJDQGZDVLGHQWL¿HGE\D'1$PLFURDUUD\DVDSRVVLEOHFDQGLGDWHLQYROYHG
in CaSR-mediated osteolysis. Indeed, in vitro, CaSR overexpression increased both 
epiregulin expression and secretion as compared to EV- or CaSR-DN-transfected 
cells. Increased epiregulin expression was also detected in osteolytic bone lesions 
from mice injected with CaSR-WT-transfected MDA-MB-231. In vitro, exposure of 
RVWHREODVWLFFHOOV+2%DQG6D26WRH[RJHQRXVHSLUHJXOLQVLJQL¿FDQWO\GHFUHDVHG
OPG mRNA expression. Exposure of osteoblastic cells to conditioned media prepared 
from CaSR-WT-transfected cells also decreased OPG expression. This effect was 
partially blocked after addition of an anti-epiregulin antibody.
Conclusions: Overexpression of a functional CaSR in metastatic breast cancer 
FHOOVGUDPDWLFDOO\DPSOL¿HVWKHLURVWHRO\WLFSRWHQWLDOWKURXJKHSLUHJXOLQPHGLDWHG
OPG downregulation.
INTRODUCTION
Breast cancer is the most common cancer among 
women worldwide. In these patients, metastatic cancer 
is the leading cause of death. Bones are a common place 
for breast cancer cells to metastasize. Within bone tissue, 
breast cancer cells activity favors osteolysis, which 
promotes hypercalcemia [1], bone pain and increases the 
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risk of pathologic fractures. Breast cancer cells and bone 
cells communicate with each other through a vicious 
circle that results in progressive bone destruction and/
or tumour growth [2]. Breast tumors from primary site 
produce parathyroid hormone related peptide (PTHrP) 
[1], which upregulates osteoblasts Receptor Activator of 
1)ț%/LJDQG5$1./SURGXFWLRQ%LQGLQJRI5$1./
WRLWVUHFHSWRU5$1.H[SUHVVHGRQRVWHRFODVWSUHFXUVRU
cells initiates their maturation and differentiation toward 
activated osteoclasts and stimlates bone resorption [3]. 
The calcium (Ca2+) released from bone resorption is 
thought to locally promote further PTHrP production 
from the metastatic tumour, thereby supporting the 
vicious circle [4]. Growth factors released from bone 
PDWUL[GHVWUXFWLRQHQDEOHWXPRUFHOOVXUYLYDODQGJURZWK
LQERQHPLFURHQYLURQPHQW7KLVSKHQRPHQRQDPSOL¿HV
the manifestation of bone metastases, which in turn 
increases the rate of bone turnover, thus feeding the 
vicious circle [2].
Initially cloned from parathyroid glands, where it 
is involved in systemic Ca2+ homeostasis [5], the calcium 
sensing receptor (CaSR) recently emerged as a new target 
ZLWKLQ WKLVYLFLRXVFLUFOH%UHDVWFDUFLQRPDVH[SUHVV WKH
&D65 2I LQWHUHVW &D65 H[SUHVVLRQ LV KLJKHU LQ EUHDVW
cancer samples from patients with bone metastasis, 
suggesting that CaSR-positive tumors are more likely to 
metastasize to the skeleton [6]. In accordance with this 
K\SRWKHVLVH[SUHVVLRQRIWKH&D65LVKLJKHULQEUHDVWFDQFHU
cell lines with relatively increased bone metastatic potential 
such as MDA-MB-231 [6]. Those cells also show a stronger 
CaSR-dependent migratory response to Ca2+ compared 
with cells with a lower metastatic potential (MCF-7, T47D) 
[7]. In malignant breast cells MCF-7 and MDA-MB-231, 
activation of the CaSR by Ca2+ stimulates PTHrP secretion 
[8]. Together, these data suggest that the large amounts of 
Ca2+ released after PTHrP-induced bone resportion could 1/ 
facilitate tumor cell migration into the bone through CaSR 
stimulation and 2/ participate to the vicious circle of bone 
resorption through CaSR induced-PTHrP secretion.
To date, our understanding on how the CaSR is 
involved in the development of osteolytic bone metastasis 
is limited to clinical observations and in vitroH[SHULPHQWDO
data. Results obtained from animal models are lacking 
to truly demonstrate these concepts. This study aimed 
to i/ develop a model allowing an in vivo demonstration 
of the involvement of the CaSR on metastatic tumor 
osteolytic potential and to ii/ investigate if CaSR activity 
FRXOGLQÀXHQFHRVWHRO\VLVWKRXJKDPHFKDQLVPGLIIHUHQW
from PTHrP modulation. For this purpose, we developed 
a model of MDA-MB-231 cells stably transfected to 
RYHUH[SUHVV HLWKHU D ZLOG W\SH RU D GRPLQDQW QHJDWLYH
(R185Q) form of the CaSR. We demonstrated that the 
RYHUH[SUHVVLRQRIDIXQFWLRQDOIRUPRIWKH&D65IDYRXUHG
MDA-MB-231 osteolytic potential when intratibially 
injected to Balb/c-Nude mice. Studies lead by DNA 
PLFURDUUD\ LGHQWL¿HG HSLUHJXOLQ DV D SRVVLEOH QHZ
candidate involved in CaSR-mediated osteolysis.
RESULTS
Stable transfection of human MDA-MB-231 
breast cancer cells
To investigate the role of the CaSR on breast cancer 
cells osteolytic potential, we used MDA-MB-231 cells, 
an estrogen-independent breast cancer cell line able to 
colonize bone [9] and to induce osteolytic metastasis [10, 
11]. MDA-MB-231 cells were stably transfected with 
plasmids containing either a full-length wild-type CaSR 
(CaSR-WT) or a functionally inactive dominant negative 
PXWDQW&D65'1&D65VHTXHQFHZDV)/$*WDJJHGLQ
its C-terminal region to discreminate between endogenous 
DQGJHQHWLFDOO\LQGXFHG&D65H[SUHVVLRQ&HOOVWUDQVIHFWHG
with the empty pcDNA3.1/Zeo(+) plasmid (Empty 
Vector (EV)) served as controls. Western blot analyses 
performed with an anti-CaSR antibody demonstrated 
that both CaSR-WT- and CaSR-DN-transfected MDA-
0% GLVSOD\HG LQFUHDVHG &D65 H[SUHVVLRQ DV
compared with EV-transfected cells (Figure 1A). The 
VDPH SUR¿OH RI H[SUHVVLRQ ZDV REWDLQHG RQ ZHVWHUQ
EORWV SHUIRUPHG ZLWK DQ DQWL)/$* DQWLERG\ )LJXUH 
&&RQ¿UPLQJWKHVHREVHUYDWLRQVDVLJQL¿FDQWLQFUHDVH
RIERWK&D65DQG)/$*H[SUHVVLRQZDVREVHUYHGZLWK
ÀRZF\WRPHWU\LQ&D65:7DQG&D65'1WUDQVIHFWHG
MDA-MB-231 as compared with EV-transfected cells 
(Figure 1B and 1D).
Dominant-negative (DN) mutations disrupt the 
activity of wild-type genes [12]. CaSR activation results 
LQ (5. SDWKZD\ DFWLYDWLRQ LQ YDULRXV FHOO W\SHV
[1315], including MDA-MB-231 cells [7]. Thus, we 
investigated CaSR functionality in EV-, CaSR-WT- and 
CaSR-DN-transfected cells through measurement of 
(5. SKRVSKRU\ODWLRQ OHYHOV DIWHU &D2+ stimulation. 
([SRVXUH RI (9WUDQVIHFWHG FHOOV WR LQFUHDVLQJ &D2+ 
FRQFHQWUDWLRQV IURP  WR  PPRO/ SURPRWHG
(5.SKRVSKRU\ODWLRQ LQDFRQFHQWUDWLRQGHSHQGHQW
PDQQHU )LJXUH ( 7KHVH HIIHFWV ZHUH VLJQL¿FDQWO\
DPSOL¿HG LQ &D65:7WUDQVIHFWHG FHOOV DV FRPSDUHG
with EV-transfected cells, while CaSR-DN-transfected 
MDA-MB-231 completely lost their abilities to respond 
to Ca2+.
CaSR-WT overexpression enhances MDA-
MB-231 osteolytic potential in vivo
7RH[DPLQHWKHLQÀXHQFHRI&D65RYHUH[SUHVVLRQ
on MDA-MB-231 osteolytic potential, EV-, CaSR-WT- or 
CaSR-DN-transfected cells were intratibially injected into 
Balb/c-Nude mice. The development of bone lesions was 
followed by X-ray up to nineteen days. A sham operated 
mouse was used as a control. Data obtained by radiography 
demonstrated that 19 days after intratibial injection, the 
osteolytic area was around 4 fold wider in mice injected 
with CaSR-WT-transfected cells as compared with mice 
which were injected with EV-transfected cells (Figure 
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$DQG%7KHH[WHQWRIRVWHRO\WLFOHVLRQVZDVVLPLODU
between mice injected with EV-transfected MDA-MB-231 
and those injected with CaSR-DN-transfected cells. 
Histomorphometric analysis showed that mice intratibially 
injected with CaSR-WT- transfected MDA-MB-231 
KDGVLJQL¿FDQWO\ ORZHU%979DVFRPSDUHGZLWKPLFH
intratibially injected with EV-transfected cells (p=0.0004) 
or CaSR-DN-transfected cells (p=0.02) (Figure 3A and 
%7KHUHZDVQRVLJQL¿FDQWGLIIHUHQFHEHWZHHQ%979
ratios of mice injected with CaSR-DN-transfected cells 
as compared with mice injected with EV-transfected cells 
(p=0.2). Skeletal tumor burden in the intratibial cavity of 
mice injected with CaSR-WT-transfected cells appeared 
VLJQL¿FDQWO\ PRUH SURQRXQFHG DV FRPSDUHG WR PLFH
injected with EV- or CaSR-DN-transfected cells, due to 
replacement of bone tissue and bone marrow with tumor 
cells (Figure 3C). No skeletal lesion was observed in the 
sham animals.
Figure 1: Expression and functionality of the CaSR in CaSR-WT-, CaSR-DN- and EV- transfected MDA-MB-231. (A, 
B, C and D)(YDOXDWLRQRIWRWDO$DQG%DQG)/$*WDJJHG&DQG'&D65H[SUHVVLRQLQ(9&D65:7DQG&D65'1WUDQVIHFWHG
0'$0%SHUIRUPHGE\ZHVWHUQEORW$DQG&DQGÀRZF\WRPHWU\%DQG'E.(YDOXDWLRQRI(5.SKRVSKRU\ODWLRQLQ0'$
0%WUDQVIHFWHGZLWKHLWKHU(9&D65:7RU&D65'1DQGH[SRVHGIRUPLQWRLQFUHDVLQJ>&D2+
0
] (1.8, 2.5 or 5 mM) (western blot). 
5HVXOWVUHSUHVHQWLQGHSHQGHQWH[SHULPHQWVSSYV(9SSYV&D65:7FXOWXUHGLQP0&D2+.
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CaSR overexpression is associated with 
increased epiregulin expression in MDA-MB-231 
cells
We hypothesized that the high osteolytic potential 
of CaSR-WT-transfected MDA-MB-231 could be 
WKH FRQVHTXHQFH RI DQ DOWHUHG H[SUHVVLRQ SDWWHUQ RI
bone-regulatory genes, other than PTHrP. Thus, a 
transcriptomic analysis was performed using RNA 
microarray in order to compare CaSR-WT- and EV-
transfected cells. Out of more than 44000 elements 
DVVHVVHG RQO\  JHQHV ZHUH GLIIHUHQWLDOO\ H[SUHVVHG
LQUHVSRQVHWR&D65RYHUH[SUHVVLRQJHQHVZHUHXS
regulated (Supplementary Table 1) and 10 genes were 
down-regulated (Supplementary Table 2). Among them, 
epiregulin (EREG), a known EGF-like ligand, showed a 
Figure 2: CaSR-WT overexpression favours MDA-MB-231 osteolytic potential in vivo. (A) X-ray images of hind limbs taken 
GD\VDIWHUPLFHLQRFXODWLRQZLWK(9&D65:7RU&D65'1WUDQVIHFWHG0'$0%$UURZRVWHRO\WLFDUHD(B)4XDQWL¿FDWLRQRI
WKHRVWHRO\WLFDUHD6KDPZDVDQDJHPDWFKHGDQLPDOZKLFKKDGQRWEHHQLQMHFWHGZLWKWXPRUFHOOVSYV&D65:7
Figure 3: Intratibial injection of CaSR-WT-transfected MDA-MB-231 lowers BV/TV ratio. (A) Micrographs of Goldners 
WULFKURPHVWDLQHGVHFWLRQVRIWLELDOPHWDSK\VLV*ROGQHU¶VWULFKURPHVWDLQLQJZDVSHUIRUPHGGD\VDIWHULQWUDWLELDOLQMHFWLRQ*UHHQERQH
±5HGERQHPDUURZDQGWXPRUFHOOVDVWHULNV(B) Bone histomorphometry measurements (BV/TV, bone volume-tissue volume ratio). 
(C)7XPRUEXUGHQ6KDPZDVDQDJHPDWFKHGDQLPDOZKLFKKDGQRWEHHQLQMHFWHGZLWKWXPRUFHOOVSSSYV
CaSR-WT-transfected cells.
Oncotarget56464www.impactjournals.com/oncotarget
3 fold up-regulation. Data obtained by quantitative RT-
3&5DQGLPPXQRF\WRFKHPLVWU\FRQ¿UPHGWKDWHSLUHJXOLQ
H[SUHVVLRQ ZDV VLJQL¿FDQWO\ LQFUHDVHG LQ &D65:7
transfected cells as compared with EV- or CaSR-DN-
transfected cells (Figure 4A and 4C). No difference was 
observed between epiregulin transcripts levels from 
(9DQG&D65'1WUDQVIHFWHGFHOOV(/,6$SHUIRUPHG
on supernatants showed increased epiregulin secretion 
in CaSR-WT-transfected cells as compared with EV- or 
CaSR-DN-transfected cells (Figure 4B).
7R FRQ¿UP WKH OLQN EHWZHHQ &D65 DFWLYLW\ DQG
epiregulin production, CaSR-WT-, CaSR-DN- and EV-
WUDQVIHFWHGFHOOVZHUHH[SRVHGIRUKRXUVWRLQFUHDVLQJ
Ca2+FRQFHQWUDWLRQVDQGPPRO/in vitro and 
HSLUHJXOLQJHQHH[SUHVVLRQZDVDVVHVVHGE\T573&5,Q
our model, Ca2+ VLJQL¿FDQWO\ LQFUHDVHGHSLUHJXOLQJHQH
H[SUHVVLRQLQ&D65:7WUDQVIHFWHG0'$0%LQD
dose dependent manner, with a 4-fold increase observed in 
FHOOVH[SRVHGWRPPRO/RI&D2+ (Figure 4D). Epiregulin 
H[SUHVVLRQZDVQRWVLJQL¿FDQWO\PRGXODWHGLQUHVSRQVHWR
Figure 4: CaSR activity increases epiregulin expression and secretion by MDA-MB-231 cells in vitro. (A) Evaluation 
RIHSLUHJXOLQ(5(*P51$H[SUHVVLRQLQHLWKHU&DV5:7&D65'1RU(9WUDQVIHFWHGFHOOVT573&5(B)(/,6$SHUIRUPHGRQ
VXSHUQDWDQWVIURP(9&D65:7DQG&D65'1WUDQVIHFWHG0'$0%WRGHWHFWHSLUHJXOLQVHFUHWLRQSRUSYV
CaSR-WT. (C),PPXQRF\FKHPLFDOHYDOXDWLRQRIHSLUHJXOLQSURWHLQH[SUHVVLRQLQ(9&D65'1RU&D65:70'$0%6FDOHEDUV
ȝP(D)(YDOXDWLRQRIHSLUHJXOLQ(5(*P51$H[SUHVVLRQLQ&DV5:7&D65'1DQG(9WUDQVIHFWHGFHOOVH[SRVHGIRUKRXUVWR
1.8, 2.5 or 5 mM of Ca2+SRUSYVFHOOVH[SRVHGWRP0&D2+5HVXOWVUHSUHVHQWLQGHSHQGHQWH[SHULPHQWV
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Ca2+ neither in EV-, nor in CaSR-DN-transfected MDA-
MB-231.
Data obtained by immunohistochemistry 
GHPRQVWUDWHGDQLQFUHDVHGHSLUHJXOLQH[SUHVVLRQZLWKLQ
osteolytic bone lesions from mice injected with CaSR-
WT-transfected MDA-MB-231 compared with bones from 
mice injected with either EV- or CaSR-DN-transfected 
cells (Figure 5).
Epiregulin decreases OPG but not RANKL 
expression in human osteoblastic cells
EGF-like ligands were recently reported to promote 
RVWHRFODVWRJHQHVLV E\ GHFUHDVLQJ 23* H[SUHVVLRQ
LQ RVWHREODVWLF FHOOV ZLWKRXW PRGXODWLRQ RI 5$1./
H[SUHVVLRQ>@:HWKXVVWXGLHGWKHHIIHFWVRIHSLUHJXOLQ
RQ WKH5$1./23*UDWLR LQ WZR W\SHVRIRVWHREODVWLF
FHOOV WKH KXPDQ RVWHREODVWLF FHOO OLQH 6D26 DQG WKH
primary human osteoblastic cells HOB. Data obtained 
E\ T573&5 GHPRQVWUDWHG WKDW H[SRVXUH RI ERWK
SaOS2 and HOB cells to increasing concentrations of 
H[RJHQRXVHSLUHJXOLQGHFUHDVHG23*JHQHH[SUHVVLRQLQ
a concentration dependent manner (Figure 6A and 6B), 
ZLWKRXWPRGXODWLRQRI5$1./H[SUHVVLRQ)LJXUH&DQG
6D).
To ascertain that CaSR activation in tumor cells is 
responsible for decreased osteoblasts OPG production, 
6D26 DQG +2% FHOOV ZHUH H[SRVHG IRU  KRXUV WR
conditioned media prepared from CaSR-WT-, CaSR-DN- 
DQG (9WUDQVIHFWHG FHOOV H[SRVHG WR  PPRO/ RI &D2+ 
IRUKRXUV([SRVXUHRI6D26DQG+2%FXOWXUHV WR
conditioned media prepared from CaSR-WT-transfected 
FHOOVGHFUHDVHG23*P51$H[SUHVVLRQE\DSSUR[LPDWHO\
50% as compared with EV- and CaSR-DN-transfected 
FHOOV)LJXUH$DQG%([SRVXUHWRFRQGLWLRQHGPHGLD
prepared from CaSR-DN and EV-transfected cells had no 
HIIHFWRQ+2%DQG6D2623*H[SUHVVLRQDVFRPSDUHG
with the control condition.
7R HYDOXDWH LI WKH GHFUHDVH RI 23* H[SUHVVLRQ
induced by conditioned medial from CaSR-WT-transfected 
Figure 5: Epiregulin expression is increased in osteolytic bone lesions from mice injected with CaSR-WT-transfected 
MDA-MB-231.,PPXQRKLVWRFKHPLFDOHYDOXDWLRQRIHSLUHJXOLQSURWHLQH[SUHVVLRQLQERQHVHFWLRQVIURPPLFHLQMHFWHGZLWK(9&D65
'1 RU &D65:70'$0% %0 ERQH PDUURZ 7% WUDEHFXODU ERQH$VWHULVN SRVLWLYH VWDLQLQJ IRU HSLUHJXOLQ ZLWKLQ LQYDGHG
RVWHRO\WLFERQHOHVLRQV6FDOHEDUVȝP
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cells depends on epiregulin secretion, the same procedure 
was reproduced using a neutralizing antibody targeting 
epiregulin. As demonstrated in Figure 7C and 7D, the 
use of the anti-epiregulin antibody partially blocked the 
GHFUHDVHRI23*H[SUHVVLRQREVHUYHGLQUHVSRQVHWRD
KRXUV H[SRVXUH WR FRQGLWLRQHG PHGLD IURP &D65:7
transfected cells, in both SaOS2 and HOB cells.
DISCUSSION
7KLV UHSRUW GHPRQVWUDWHG WKDW KLJK H[SUHVVLRQ RI
a functional CaSR conferred osteolytic advantage to 
MDA-MB-231 cells when intratibially injected to Balb/c-
Nude mice in vivo. It also provided evidence that CaSR 
DFWLYDWLRQLQ0'$0%FHOOVSURPRWHGWKHH[SUHVVLRQ
and secretion of epiregulin, an EGF-like ligand, which 
GHFUHDVHG23*H[SUHVVLRQLQRVWHREODVWLFFHOOV
Stable transfection of MDA-MB-231 cells with 
plasmids containing either a full-length functional 
wild-type CaSR (CaSR-WT) or a functionally inactive 
dominant negative mutant (CaSR-DN) or an empty 
vector, and their subsequent intratibial injection into 
Balb/c-Nude mice allowed us to create an accurate model 
to study the involvment of the CaSR in metastatic bone 
osteolysis. A dramatical osteolysis had been observed 
after injection with MDA-MB-231 transfected to 
RYHUH[SUHVVDIXQFWLRQDO&D65&D65:7DVFRPSDUHG
with mice injected with EV- and CaSR-DN-transfected 
cells. This suggests that a high level of functional CaSR 
may be necessary for metastatic breast cancer cells to 
promote bone osteolysis. These data support observations 
from Mihai et al., who reported that high tumor CaSR 
H[SUHVVLRQVWURQJO\DVVRFLDWHVZLWKWKHSUHVHQFHRIERQH
metastases [6]. Of note, skeletal tumor burden was more 
Figure 6: Epiregulin decreases OPG but not RANKL expression in osteoblastic cells SaOS2 and HOB. (A, B, C and D) 
(YDOXDWLRQRIRVWHRSURWHJHULQ23*$DQG%DQG5$1./&DQG'P51$H[SUHVVLRQLQ6D26$DQG&DQG+2%%DQG'FHOOV
H[SRVHGIRUKRXUVWRUHFRPELQDQWHSLUHJXOLQT573&5SRUSYVFRQWUROFRQGLWLRQZLWKRXWHSLUHJXOLQSRU
SYVFHOOVH[SRVHGWRQJP/RIHSLUHJXOLQ5HVXOWVUHSUHVHQWLQGHSHQGHQWH[SHULPHQWV
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pronounced within the intratibial cavity of mice injected 
with CaSR-WT-transfected cells than in mice injected with 
EV- or CaSR-DN-transfected cells. This was associated 
ZLWKLQFUHDVHGH[SUHVVLRQRI.LDFHOOXODUPDUNHURI
proliferation, within osteolytic lesions from mice injected 
with CaSR-WT-transfected cells (Supplementary Figure 
1). This suggests that the high amounts of Ca2+ released 
at sites of bone resorption might promote CaSR-induced 
MDA-MB-231 cell proliferation. However, data obtained 
in vitro showed that Ca2+-induced CaSR activation did not 
modulate neither the proliferation, nor the apoptosis of 
EV-, CaSR-DN- or CaSR-WT-transfected MDA-MB-231 
FHOOV 6XSSOHPHQWDU\ )LJXUH $ DQG % 7R H[SODLQ
this phenomenon, we hypothesized that the osteolysis 
induced in vivoE\WKH0'$0%RYHUH[SUHVVLQJWKH
functional CaSR might have favored the release of growth 
IDFWRUVVXFKDV7*)ȕIURPWKHERQHPDWUL[ZKLFKLQWXUQ
might have favored tumor cell proliferation.
In vitro, activation of the CaSR with Ca2+, 
spermine, aminoglycoside antibiotics or allosteric (type 
II) calcimimetics increased PTHrP secretion by breast 
cancer cells [8, 17]. Since PTHrP secretion by metastatic 
FHOOV LQFUHDVHV RVWHREODVWV 5$1./ SURGXFWLRQ DQG
subsequent osteclastogenesis, the current prevailing view 
is that CaSR osteolytic potential comes from its ability to 
increase metastatic breast cancer cells PTHrP secretion. We 
hypothesized that, apart from PTHrP secretion, high CaSR 
DFWLYLW\ PLJKW PRGXODWH WKH H[SUHVVLRQ SDWWHUQ RI RWKHU
bone regulatory genes. Data obtained from comparative 
WUDQVFULSWRPLF DQDO\VLV LGHQWL¿HG HSLUHJXOLQ ZKLFK
H[SUHVVLRQLVWULSOHGLQ&D65:7WUDQVIHFWHG0'$0%
as compared to EV-transfected cells, as a potential candidate.
Figure 7: CaSR-mediated epiregulin secretion by MDA-MB-231 decreases OPG expression in osteoblastic cells.  
(A and B)(YDOXDWLRQRI23*P51$H[SUHVVLRQ LQ6D26 $DQG+2%%FHOOV H[SRVHG IRUKRXUV WRFRQGLWLRQHGPHGLD &0
SUHSDUHGDIWHUH[SRVXUHRI&D65:7&D65'1RU(9WUDQVIHFWHG0'$0%WRP0RI&D2+
0
 T573&5SYVFRQWURO
FRQGLWLRQ&7P0RI&D2+
0
SRUSYV&0IURP&D65:7WUDQVIHFWHGFHOOV(C and D) Evaluation of OPG mRNA 
H[SUHVVLRQLQ6D26&DQG+2%'FHOOVH[SRVHGIRUKRXUV WR&0IURP&D65:7WUDQVIHFWHG0'$0%ZLWKRUZLWKRXW
DQWLHSLUHJXOLQDQWLERG\T573&5SYVXQWUHDWHGFHOOVSYV&0IURP&D65:7WUDQVIHFWHGFHOOVZLWKRXWDQWLHSLUHJXOLQ
DQWLERG\5HVXOWVUHSUHVHQWLQGHSHQGHQWH[SHULPHQWVSHUIRUPHGLQWULSOLFDWH
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Epiregulin belongs to the epidermal growth factor 
(EGF) family of peptide growth factors [18]. EGF-
like ligands and their cognate receptors modulate cell 
functions in a variety of ways, including proliferation, 
survival, adhesion, migration and differentiation. In this 
work, data obtained in vitro FRQ¿UPHG WKDW HSLUHJXOLQ
H[SUHVVLRQ DQG VHFUHWLRQ ZHUH KLJKO\ XSUHJXODWHG LQ
CaSR-WT-transfected cells compared to CaSR-DN- or 
EV-transfected cells. This was associated with increased 
epiregulin detection in osteolytic lesions from mice 
intratibially injected with CaSR-WT-transfected MDA-
MB-231 compared to mice injected with CaSR-DN- or 
EV- transfected cells. This phenomenon may result both 
IURPWKHKLJKOHYHORIHSLUHJXOLQH[SUHVVHGLQ&D65:7
transfected cells and the increased tumor burden observed 
LQ UHVSRQVH WRKLJK&D65DFWLYLW\&RQ¿UPLQJ WKH OLQN
EHWZHHQ&D65DFWLYLW\DQGHSLUHJXOLQJHQHH[SUHVVLRQ
Ca2+VWLPXODWLRQRIWKHIXQFWLRQDO&D65RYHUH[SUHVVHGLQ
MDA-MB-231 cells concentration-dependently increased 
HSLUHJXOLQ P51$ H[SUHVVLRQ ZKLOH QR GLIIHUHQFH ZDV
seen neither in EV-, nor in CaSR-DN-transfected MDA-
MB-231.
In a recent study, Zhu et al. reported that EGF-
like ligands strongly stimulate osteoclast formation 
in co-cultures of osteoblastic cells and bone marrow 
macrophages (BMMs) through the down-regulation 
of osteoblast OPG and MCP-1 [16]. In this study, co-
cultures with MDA-MB-231 had similar effects on 
RVWHREODVWVH[SUHVVLRQRI23*DQG0&37KRVHHIIHFWV
could be partially abolished by EGFR inhibitor. Thus, 
the authors reasoned that EGF-like ligands, similarly to 
PTHrP, may increase osteolytic lesions [16]. In our model, 
RYHUH[SUHVVLRQ RI D IXQFWLRQDO &D65 DPSOL¿HV 0'$
MB-231 osteolytic potential and epiregulin secretion in 
vivo. We thus hypothesized that CaSR effects on MDA-
MB-231 osteolytic potential could be the consequence 
RIGHFUHDVHGRVWHREODVWV23*H[SUHVVLRQLQUHVSRQVHWR
increased epiregulin secretion by metastatic cells.
,Q OLQH ZLWK WKLV K\SRWKHVLV H[SRVXUH RI ERWK
HOB and SaOS2 cells to increasing doses of epiregulin 
GHFUHDVHG 23* JHQH H[SUHVVLRQ LQ D FRQFHQWUDWLRQ
GHSHQGHQW PDQQHU &RQ¿UPLQJ SUHYLRXV GDWD REWDLQHG
from Zhu et al. [16] we did not observe any modulation of 
RVWHREODVWV5$1./H[SUHVVLRQLQUHVSRQVHWRH[RJHQRXV
epiregulin. Conditioned media prepared from CaSR-WT-
transfected cells decreased both SaOS2 and HOB OPG 
P51$H[SUHVVLRQE\DSSUR[LPDWHO\DVFRPSDUHG
with EV- and CaSR-DN-transfected cells. The use of a 
neutralizing antibody targeting epiregulin partially blocked 
this phenomenon, demonstrating that CaSR-mediated 
decrease of OPG in osteoblastic cells partly depends on 
epiregulin secretion. Since CaSR activation on tumor cells 
promotes the secretion of PTHrP, which is also known to 
block OPG production [3], the fact that the neutralizing 
antibody targeting epiregulin does not totally block CaSR-
PHGLDWHGGHFUHDVHLQ23*H[SUHVVLRQLVQRWVXUSULVLQJ
In prostate cancer cells, CaSR stimulation transactivates 
WKH(*)5OHDGLQJWR(5.SKRVSKRU\ODWLRQDQGUHVXOWDQW
PTHrP secretion [19]. Based on this observation, 
ZH FDQQRW H[FOXGH LQ RXU VWXG\ WKDW &D65PHGLDWHG
Figure 8: Involvement of the CaSR-epiregulin axis on the vicious circle of bone metastasis-induced osteolysis. At sites of 
bone resorption, the high amounts of Ca2+
0
 released (1)FDQDFWLYDWHWKH&D65H[SUHVVHGE\EUHDVWFDQFHUGHULYHGPHWDVWDWLFFHOOV(2), which 
promotes epiregulin synthesis (3) and secretion (4)(SLUHJXOLQ¿[DWLRQRQLWVUHFHSWRUVH[SUHVVHGE\RVWHREODVWVLQKLELWV23*V\QWKHVLV(5), 
WKXVIDYRULQJLQWHUDFWLRQVEHWZHHQ5DQN/H[SUHVVHGE\RVWHREODVWVDQGLWVUHFHSWRU5$1.H[SUHVVHGE\LPPDWXUHRVWHRFODVWV7KLVIDYRUV
osteoclastogenesis and in turn increases the rate of bone turnover, thus feeding the vicious circle.
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epiregulin secretion might locally transactivate EGFR and 
improve PTHrP secretion by MDA-MB-231, which would 
indirectly worsen OPG inhibition in osteoblasts.
It would have been interesting to assess variations 
in osteoclasts number as a consequence of CaSR-
induced osteolysis. However, in our model, the osteolytic 
activity of CaSR-WT-transfected MDA-MB-231 was so 
strong within 19 days, that the tumor invaded almost the 
whole bone. Therefore, there were almost no bone, and 
consequently no bone cells, left within those lesions. This 
would have biased the assessment of osteoclasts number.
To conclude, our data revealed an important role 
IRUWKH&D65HSLUHJXOLQD[LVRQPHWDVWDWLFEUHDVWFDQFHU
cells osteolytic potential. At site of bone resorption (Figure 
8), the activation by Ca2+ RI WKH &D65 H[SUHVVHG E\
metastatic breast cancer cells favors epiregulin synthesis 
and secretion, which in turn acts on osteoblastic cells to 
reduce OPG synthesis. By reducing the level of OPG 
released in bone microenvironment, the CaSR-epiregulin 
D[LV PLJKW LQFUHDVH ERQH UHVRUSWLRQ WKURXJK LQFUHDVHG
RVWHRFODVWRJHQHVLV(*)5LQKLELWRUVVXFKDVFHWX[LPDE
ZKLFKWDUJHWVWKHUHFHSWRULWVHOIRUJH¿WLQLEDQGHUORWLQLE
(which target EGFR tyrosine kinase), were recently shown 
WRHI¿FLHQWO\UHGXFHRVWHRO\WLFOHVLRQVSURPRWHGin vivo 
E\$'$076DQG003RYHUH[SUHVVLQJ0'$0%
which secretes high amount of EGF like ligand. In line 
ZLWK WKLV VWDWHPHQW VLJQL¿FDQW UHOLHIRIERQHSDLQZDV
observed in patients with bone metastasis in a clinical trial 
of the EGFR tyrosine kinase inhibitor. Together with these 
data, our work sheds lights on EGFR inhibitors as possible 
therapeutic strategies to prevent CaSR-mediated osteolytic 
bone metastasis.
MATERIALS AND METHODS
Cell lines and stable transfections
CaSR-WT and CaSR-DN cDNAs (CaSR R185Q) 
which have been described previously were used for the 
transfection of MDA-MB-231 cells (ATCC® HTB-26TM) 
[20]. The coding regions of CaSR-WT and CaSR-DN 
FRQWDLQLQJD)/$*WDJJHGVHTXHQFHZHUHDPSOL¿HGE\
polymerase chain reaction (PCR) and subcloned at the 
HindIII/XbaI sites of the pcDNA3.1/Zeo(+) vector (V860-
20, Invitrogen). MDA-MB-231 were transfected with 
pcDNA3.1/Zeo(+) vector containing CaSR-WT cDNA 
RU&D65'1F'1$XVLQJ/LSRIHFWDPLQHFDWDORJ
#11668-027, Invitrogen). MDA-MB-231 transfected 
with the empty vector (EV) were used as controls. Stably 
transfected cells were selected by growing them in zeocin-
containing medium and cloned by limiting dilution. These 
cells were then routinely cultured in MEM (catalog 
06LJPD6W/RXLV02VXSSOHPHQWHGZLWK
IHWDOERYLQHVHUXP)%6*OXWD0D[RI3HQLFLOOLQ
6WUHSWRP\FLQ FRPSOHWH 0(0 DQG  PJP/ ]HRFLQ
FDWDORJ5,QYLWURJHQ)RUWKHVWXG\RI0$3.
(5.DFWLYDWLRQVWDEO\ WUDQVIHFWHG0'$0%
000 cells/well; 6-well plates) were starved for 4 hours and 
stimulated for 10 minutes with increasing concentrations 
of Ca2+RUPPRO/&RQGLWLRQHGPHGLD&0
PHQWLRQHGLQWKHPDQXVFULSWZHUHSUHSDUHGE\H[SRVXUHRI
EV-, CaSR-WT- or CaSR-DN-transfected MDA-MB-231 
WRPPRO/RI&D2+ for 24 hours.
The cell line of human osteosarcoma (SaOS2) was 
purchased from ATCC (ATCC® HTB-85TM) and routinely 
cultured in complete DMEM (catalog #M5677, Sigma, 
6W /RXLV 02 3ULPDU\ FXOWXUHV RI KXPDQ RVWHREODVWV 
(HOB) were purchased from Promocell (catalog #C-
12720, Heidelberg, Germany) and cultured in Osteoblast 
Growth Medium (catalog # C-27001, Promocell, 
Heidelberg, Germany).
Western blot analysis
%ULHÀ\ FHOOV ZHUH ZDVKHG RQFH ZLWK 3%6 DQG
homogenized at 4°C in a lysis buffer (10mM Tris-HCl, 
150 mM NaCl, 10% glycerol, 2 mM Na3VO4 and 
protease inhibitors pH 7.4) containing either 1% NP40 (for 
the study of p42/44 proteins) or 1% SDS (for the study 
RI&D65H[SUHVVLRQ3URWHLQVZHUHWKHQVHSDUDWHGLQ
or 10% SDS-PAGE. After electrophoresis, samples were 
transferred to nitrocellulose membranes, blocked with 
5% skimmed milk in TBS/0.1% v/v Tween 20 for 1 h, 
washed with TBS/Tween and incubated overnight at 4°C 
ZLWKSULPDU\DQWLERGLHVPRXVHPRQRFORQDODQWL&D65
 FDWDORJ 1% 1RYXV %LRORJLFDOV
PRXVH PRQRFORQDO DQWL)/$* 0  FDWDORJ
#200471, Agilent Technologies), rabbit polyclonal anti-
SKRVSKR(5.  DQG UDEELW SRO\FORQDO DQWL
(5.FDWDORJDQGUHVSHFWLYHO\
Cell Signaling, Danvers, MA). Antibodies were diluted in 
5% milk TBS/Tween. Blots were washed with TBS/Tween 
DQGLQFXEDWHGZLWKDSSURSULDWHKRUVHUDGLVKSHUR[LGDVH
FRQMXJDWHGVHFRQGDU\DQWLERG\FDWDORJVF
and #sc-2004 for anti-mouse and anti-rabbit respectively, 
Santa Cruz Biotechnology). After washing with TBS/
Tween, blots were developed with the chemiluminescence 
PHWKRG(&/FDWDORJ531$PHUVKDP$\OHVEXU\
8.DQGWKHQSUREHGZLWKPRXVHPRQRFORQDODQWLȕDFWLQ
DQWLERG\  FDWDORJ $ 6LJPD 6W /RXLV
02IROORZLQJWKHVDPHPHWKRGDQGOHYHOVRIH[SUHVVLRQ
were corrected for minor differences in loading.
Flow cytometry analysis
MDA-MB-231 were detached using cell 
GLVVRFLDWLRQVROXWLRQFDWDORJ&6LJPD6W/RXLV
02DQGSHUPHDELOL]HGXVLQJWKH&\WR¿[&\WRSHUP70
3OXV ¿[DWLRQSHUPHDELOL]DWLRQ NLW FDWDORJ 
%' %LRVFLHQFHV /H 3RQW GH &ODL[ )UDQFH IROORZLQJ
manufacturers instructions. Cells were then incubated for 
1 h at 4°C with primary antibody (mouse mAb anti-CaSR 
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&$''FDWDORJDE$EFDPGLOXWLRQ
IURP RULJLQDO XQLW RU PRXVH PRQRFORQDO DQWL)/$*
0  FDWDORJ  $JLOHQW 7HFKQRORJLHV
or control isotype (catalog #X0943, Dako-Cytomation, 
Glostrup, Denmark), then washed in PBS containing 
0.5% BSA, and labelled using polyclonal goat anti-
mouse immunoglobulins/RPE (catalog # R0480, Dako-
&\WRPDWLRQ*ORVWUXS'HQPDUNGLOXWLRQ3URWHLQ
H[SUHVVLRQZDVDVVHVVHGE\ÀRZF\WRPHWU\XVLQJ)$&6
&DQWR,,%'%LRVFLHQFHV/H3RQWGH&ODL[)UDQFH7KH
results are presented in per cent of control condition (EV).
Microarrays analysis
Total RNA from EV- and CaSR-WT-transfected 
MDA-MB-231 cells were isolated using RNeasy Mini 
.LW FDWDORJ  4LDJHQ )UDQFH &RXUWDERHXI
$IWHU WUHDWPHQW ZLWK WXUER '1DVH /LIH WHFKQRORJLHV
Illkirch, France), the quality of RNA samples was tested 
using RNA 6000 Nano kit and analyzed with Agilent 
2100 Bioanalyser. Microarrays analysis was performed 
by PEGASE Biosciences (France) from Agilent Whole 
+XPDQ*HQRPH[.DUUD\V
ELISA for epiregulin
Quantitative detection of soluble epiregulin was 
performed from supernatants of EV-, CaSR-WT- or CaSR-
DN-transfected MDA-MB-231 using a commercially 
available kit (SEB945Hu 96 Tests, Cloud-Clone Corp.) 
according to manufacturer's instructions.
Quantitative reverse transcription PCR  
(qRT-PCR)
7RWDO51$ZDVH[WUDFWHGIURP(9&D65:7RU
CaSR-DN-transfected MDA-MB-231 using the RNeasy 
0LQL.LWFDWDORJ4LDJHQ)UDQFH&RXUWDERHXI
RNA was reverse transcribed into cDNA using the High 
&DSDFLW\ F'1$ 5HYHUVH 7UDQVFULSWLRQ .LW´ FDWDORJ
#4368813, Applied Biosystems, Foster City, CA, USA) 
according to manufacturer's instructions. The qRT-PCR 
was performed on StepOnePlus real time PCR system 
(Applied Biosystems, Foster City, CA, USA) using gene-
VSHFL¿FSULPHUVIRUHSLUHJXOLQFDWDORJ47
23* FDWDORJ  47 RU 5$1./ FDWDORJ 
QT00215614) (QuantiTect Primer Assay, Qiagen France, 
&RXUWDERHXI 51$ H[SUHVVLRQ RI WKH GLIIHUHQW JHQHV
ZDVFRUUHFWHGIRU*$3'+XVLQJWKHIROORZLQJSULPHUV
forward 5_atcaccatcttccaggagcga_3 and reverse 5_
agccttctccatggtggtgaa_3.
Animal studies
All procedures, including housing and care 
RI WKH PLFH HXWKDQDVLD DQG H[SHULPHQWDO SURWRFROV
were conducted in accordance with a code of practice 
established by the local ethical committee of the 
8QLYHUVLW\ RI /\RQ /\RQ )UDQFH 7KLV VWXG\ ZDV
monitored on a routine basis by a veterinarian to ensure 
continued compliance with the proposed protocols.
)LYHZHHNVROGIHPDOH%$/%FKRPR]\JRXVQX
nu) athymic mice were purchased from Charles River 
(Saint Germain sur l'Arbresle, France) and distributed 
in 3 groups (7 animals/group, plus a sham-operated 
mouse). After one week of acclimation, the mice were 
anesthetized by intraperitoneal injection of a solution (20 
ȝOJFRQWDLQLQJPJP/RINHWDPLQHDQGPJP/RI
[\OD]LQLQVDOLQHVROXWLRQ1D&ODQGUHFHLYHGDQ
intratibial injection of 100000 cells (EV, CaSR-WT and 
CaSR-DN) into the right hind limb. A Sham operated 
mouse was used as a control.
On days 7, 14 and 19 after tumor cell inoculation, 
radiographs of anesthetized mice were taken with the use 
RI0,15¿OP.RGDN5RFKHVWHU1<LQDQ0;
FDELQHW;UD\V\VWHP)D[LWURQ;UD\&RUS:KHHOLQJ
,/2VWHRO\WLFOHVLRQVZHUHLGHQWL¿HGRQUDGLRJUDSKVDV
radiolucent lesions in the bone. The area of the osteolytic 
lesions was measured using a Visiolab2000 computerized 
LPDJH DQDO\VLV V\VWHP ([SORUD 1RYD DQG WKH H[WHQW
RIERQHGHVWUXFWLRQSHUDQLPDOZDVH[SUHVVHGLQVTXDUH
PLOOLPHWHUV $QHVWKHWL]HG PLFH ZHUH VDFUL¿FHG DIWHU
radiography on day 19 after tumor cell inoculation.
Bone histomorphometry and histology
Besides radiography, tumor growth and osteolytic 
lesions were analyzed by histology. For this purpose, 
WLELDH IURP DQLPDOV ZHUH ¿[HG GHFDOFL¿HG ZLWK 
('7$3)$DQGHPEHGGHG LQSDUDI¿Q6HFWLRQRI
ȝP ZHUH VWDLQHG ZLWK *ROGQHU¶V 7ULFKURPH DQG XVHG
for histologic and histomorphometric analyses by means 
of a computerized image analysis system (Visiolab 2000). 
Histomorphometric measurements (i.e. bone volume to 
tissue volume [BV/TV] ratios) were performed in a standard 
zone of the tibial metaphysis, situated at 0.5 mm from the 
growth plate, including cortical and trabecular bones. The 
BV/TV ratio represents the percentage of bone tissue.
Immunohistochemistry for epiregulin
6HFWLRQRIȝPZHUHGHSDUDI¿QL]HGDQGLQFXEDWHG
in sodium citrate (1M, pH=6) during 20 min at 100°C for 
DQWLJHQUHWULHYDO6HFWLRQZHUHWKHQ¿[HGZLWKLFHFROG
paraformaldehyde (PFA) for 5 min at room temperature 
57 DQG TXHQFKHG LQ  PPRO/ JO\FLQ3%6 IRU
additional 10 min. Tissues were then permeabilized for 10 
min at RT with 0.1% triton X-100 in PBS containing 1% 
%6$1RQVSHFL¿FELQGLQJRIWKHDQWLERG\ZDVEORFNHGE\
incubation in a blocking solution (1% BSA in PBS) for 30 
min at RT. Sections were then incubated overnight at 4°C 
with primary antibody (goat polyclonal IgG anti-epiregulin, 
5	'6\VWHPV$)GLOXWLRQIURPRULJLQDOXQLW
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prepared in PBS containing 1% BSA. Bone sections 
were then rinsed and incubated with secondary antibody 
$OH[D)OXRU 'RQNH\ DQWLJRDW ,J* ,QYLWURJHQ
$GLOXWLRQIURPRULJLQDOXQLWSUHSDUHGLQ3%6
1% BSA, for 1 hr at RT. Samples were then widely washed 
in PBS. Nuclei were then counterstained with Hoechst and 
slides were mounted in Mowiol solution (Calbiochem®, 
0RZLRO  IRU ÀXRUHVFHQW GHWHFWLRQ 7KH VDPH
SURWRFROZDVSHUIRUPHGWRGHWHFWHSLUHJXOLQH[SUHVVLRQRQ
0'$0%PRQROD\HUVRQFRYHUVOLSVH[FHSWWKDWWKH
step of sodium citrate antigen retrieval was skipped.
Statistical analysis
StatView v5.0 (version 5.0; SAS Institute, Inc.) 
was used for statistical analysis. Normally distributed 
data are presented as means ± Standard Error of the Mean 
(SEM) and non-normally distributed data as medians and 
PLQLPXPDQGPD[LPXPYDOXHV.UXVNDO:DOOLVWHVWZDV
used to compare the three groups for in vivoH[SHULPHQWV
To account for multiple testing, Dunns multiple 
comparison test was performed. All statistical tests were 
WZRVLGHG)RUT573&5DQG(/,6$WHVWUHVXOWVDRQH
way ANOVA test was used to evaluate if differences 
EHWZHHQ JURXS PHDQV ZHUH VWDWLVWLFDOO\ VLJQL¿FDQW 3
YDOXHVRIZHUHFRQVLGHUHGVWDWLVWLFDOO\VLJQL¿FDQW
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